Raav vector compositions and methods for the treatment of choroidal neovascularization
CA 2479167 A1 · Owner: Hauswirth, William, W. · Inventors: Berns, Kenneth, I.; Campochiaro, Peter, A.; Hauswirth, William, W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular, the invention provides gene therapy methods for the prevention, long-term treatment and/or amelioration of symptoms of a variety of conditions and disorders in a mammalian eye including, for example , blindness, loss of vision retinal degeneration, macular degeneration and , related disorders …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 20, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.